

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-6 (Cancelled).

7 (Currently amended). A pharmaceutical composition for the treatment of endometriosis, comprising a TNF antagonist and a pharmaceutically acceptable carrier.

8 (Original). The pharmaceutical composition of claim 7, wherein said TNF antagonist is a polypeptide able to bind a specific epitope of TNF in such a way that TNF is no longer able to bind a membrane-bound TNF receptor.

9 (Currently amended). The pharmaceutical composition of claim [[8]] 7, wherein said TNF antagonist is a receptor molecule, derivative or a fragment thereof which binds to TNF.

10 (Currently amended). The pharmaceutical composition of claim [[9]] 7, wherein said TNF antagonist is a receptor molecule [[is]] selected from the group consisting of TNF-RI and TNF-RII.

11 (Currently amended). The pharmaceutical composition of claim [[9]] 7, wherein said ~~receptor molecule~~ TNF antagonist is the extracellular domain of TNF-RI.

12(Currently amended). The pharmaceutical composition of claim [[9]] 7, wherein said ~~receptor-molecule~~ TNF-antagonist is human soluble recombinant TNF-RI.

13(Currently amended). The pharmaceutical composition of claim [[9]] 7, wherein said ~~receptor-molecule~~ TNF antagonist is a TNF receptor multimeric molecule or a functional portion thereof.

14(Currently amended). The pharmaceutical composition of claim [[13]] 7, wherein said TNF antagonist is a TNF receptor multimeric molecule which comprises all or a functional portion of two or more extracellular domains of TNF receptors linked via one or more polypeptide linker.

15(Currently amended). The pharmaceutical composition of claim [[9]] 7, wherein said ~~receptor-molecule~~ TNF antagonist is an immunoreceptor fusion molecule or a functional portion thereof.

16(Currently amended). The pharmaceutical composition of claim [[15]] 7, wherein said TNF antagonist is an immunoreceptor fusion molecule which comprises all or a functional portion of TNF receptor and an immunoglobulin chain.

17(Original). The pharmaceutical composition of claim 7, wherein said TNF antagonist is an anti-TNF antibody or a fragment thereof.

18(Currently amended). The pharmaceutical composition of claim 17, wherein said anti-TNF antibody or fragment thereof is selected from the group consisting of a chimeric monoclonal antibody, a humanized monoclonal antibody, and fragments thereof.

19(New). The pharmaceutical composition of claim 1, wherein said TNF antagonist is a sequestering or a signaling antagonist.